New drug TR-002 enters human testing for Hard-to-Treat cancers
NCT ID NCT07189195
First seen Nov 01, 2025 · Last updated Jun 21, 2026 · Updated 37 times
Summary
This early-phase trial is testing a new chemotherapy drug called TR-002 in 52 adults with advanced solid tumors or pancreatic cancer that has spread or cannot be removed by surgery and no longer responds to standard treatments. The main goals are to find the safest dose and to check for side effects. Researchers will also watch for any signs that the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of California Davis Comprehensive Cancer Center
RECRUITINGSacramento, California, 95817, United States
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
TR-002 (a chemotherapy drug called bisaminoquinoline derivative)
What this could lead to
If this trial succeeds, it could point toward a new treatment option for people with advanced solid tumors or pancreatic cancer that has stopped responding to standard therapies.
What could go wrong
This is a very early Phase 1 trial with only 52 participants, so the drug may prove unsafe or ineffective. It is not yet known if TR-002 will shrink tumors or improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.